Surfactant replacement therapy for Respiratory Distress Syndrome (RDS) in p
remature neonates has been established as an effective treatment, although
significant mortality and morbidity remain. In Curacao, surfactant became a
vailable as a therapeutic option in 1994. A retrospective cohort study was
performed to describe the results of surfactant treatment in premature newb
orns with RDS in Curacao between 1994 and 1998. Of 429 infants admitted to
the study hospital in this period, 7.5% (n=32) developed RDS and were treat
ed with surfactant. Twenty-five per cent (n=8) of these infants died, most
of them in the first year of surfactant treatment. Twenty-eight per cent (n
=9) developed bronchopulmonary dysplasia (BPD), the most frequently observe
d complication, The highest incidence of BPD (44%) was found in the very lo
w birth weight infants (750-1500 g); all infants with BPD were 27-30 weeks
of gestational age. The duration of ventilator dependence was significantly
associated with the development of BPD (p < 0.05). No other risk factors f
or complications during the treatment course could be identified. The mean
time between birth and the first surfactant treatment was more than nine ho
urs. In this study, we found low incidence rates of RDS and BPD, and a cons
iderable mortality in surfactant treated newborns. This pilot study shows t
hat surfactant treatment of premature infants is feasible in Curacao. Earli
er administration of surfactant, preferably within 2-3 hours after birth, i
s expected to lower the risk of death and oxygen dependence.